MedTrace Logo

Alpha-bisabolol for Onychomycosis Treatment

NCT04940520 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-30

No results posted yet for this study

Summary

Clinical, interventional, longitudinal study with random sampling. 60 patients will be divided into three groups, group A: control group, drug recommended by the Brazilian Society of Dermatology, group B: alpha bisabolol-based product associated with low-level laser therapy, and group C: alpha bisabolol based product. The topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days. Areas of the lesions will be compared.

Conditions

  • Onychomycosis

Interventions

BIOLOGICAL

Drug recommended by the Brazilian Society of Dermatology

Using a drug recommended by the Brazilian Society of Dermatology, twice a day.

COMBINATION_PRODUCT

Alpha bisabolol product and laser

Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.

BIOLOGICAL

Alpha bisabolol product

Using alpha bisabolol-based product twice a day

Sponsors & Collaborators

  • Universidade do Vale do Sapucai

    lead OTHER

Principal Investigators

  • Adriana R dos Anjos Mendonça, PhD · Vale do Sapucaí University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-11-30
Completion
2021-05-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04940520 on ClinicalTrials.gov